Solara Active Pharma Sciences Limited reported a consolidated net profit of ₹10.52 crore for the quarter ended June 30, 2025. Total income for the quarter stood at ₹320.13 crore. The board also approved the appointment of Mr. Rajesh Patro as the Chief Risk Officer of the company.
Q1 FY26 Financial Results (Consolidated) (in ₹ crore)
Particulars
Q1 FY26
Q4 FY25
Q1 FY25
FY25
Revenue from operations
319.15
273.01
363.49
1,283.76
Other Income
0.98
5.95
0.56
8.32
Total Income
320.13
278.96
364.05
1,292.08
Cost of materials consumed
165.14
143.67
137.10
581.66
Purchases of stock-in-trade
-
5.05
5.75
-
Changes in inventories of finished goods, stock-in-trade and work in progress
-
(18.67)
(30.63)
64.47
Employee benefits expense
53.64
52.29
55.02
211.69
Finance costs
23.90
29.12
30.87
114.81
Depreciation and amortisation expenses
23.58
24.30
25.07
99.25
Other expenses
62.02
57.26
64.98
239.38
Total expenses
309.61
281.06
377.51
1,291.54
Profit/(loss) before exceptional items and tax
10.52
(2.10)
(13.46)
0.54
Profit/(loss) before tax
10.52
(2.10)
(13.46)
0.54
Profit/(loss) for the period/year
10.52
(2.10)
(13.46)
0.54
Total comprehensive income/(loss) for the period / year
10.51
(2.72)
(13.47)
1.52
Paid-up equity share capital (face value of Rs. 10/- each)
40.25
40.21
40.25
40.25
Earnings per equity share (face value of Rs. 10/- each) (not annualised for quarters) (a) Basic (in Rs.)
2.46
(0.93)
(3.50)
0.14
Earnings per equity share (face value of Rs. 10/- each) (not annualised for quarters) (b) Diluted (in Rs.)
2.46
(0.93)
(3.50)
0.14
Financial Performance
The consolidated financial results for the quarter ended June 30, 2025, were reviewed by the Audit Committee and approved by the Board of Directors on July 25, 2025. Deloitte Haskins & Sells LLP, the statutory auditors, have expressed an unmodified conclusion in respect of the limited review for the quarter.
Notes on Financials
The Group has accumulated losses of ₹305.11 crore, and its net current liabilities exceed its net current assets by ₹60.76 crore as of June 30, 2025. To mitigate this, the Parent expects to raise ₹134.99 crore through the pending final call of its rights issue. The Board of Directors have approved the preparation of the financial results on a going concern basis, expecting renewal of working capital facilities and increased revenues and margins.
Business Restructuring
The Board of Directors had discussed a proposal to explore the demerger of the CRAMS and Polymers business into an independent listed entity and granted in-principle approval on January 24, 2025. Consequently, Synthix Global Pharma Solutions Limited was incorporated as a wholly-owned subsidiary on April 29, 2025.
Standalone Financial Results
The standalone financial results for the quarter ended June 30, 2025, show a total income of ₹320.13 crore and a profit before tax of ₹10.53 crore.
